Active, not recruiting
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
NCT05460767
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
- First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China